Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis
Frontiers in Psychiatry · 24.06.2026 · 17
DOI: 10.3389/fpsyt.2026.1846995 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Psychiatry, online erschienen am 24.06.2026. Verfasst von Kankan Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Beijing Chaoyang Third Hospital, Beijing, China. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antipsychotic-induced metabolic syndrome complicates the clinical management of schizophrenia. This investigation seeks to examine berberine’s efficacy and safety as adjunctive therapy in schizophrenia patients with metabolic syndrome.
Methods
A thorough literature search was executed across international (PubMed, Cochrane Library, EMBASE) and Chinese (China National Knowledge Infrastructure, WanFang Data) databases to retrieve randomized controlled trials (RCTs) examining adjunctive berberine for schizophrenia with metabolic syndrome. Data extraction and synthesis were conducted by three independent reviewers employing RevMan 5.3 software.
Results
Three eligible RCTs (n = 233) were incorporated. Adjunctive berberine demonstrated superior efficacy over controls in reducing body weight (standardized mean difference (SMD) = −0.56, I² = 0%; P = 0.0003), body mass index (SMD = −0.51, I² = 0%; P = 0.0001), waist circumference (SMD = −0.31, I² = 20%; P = 0.04), total cholesterol (mean difference (MD) = −0.43, I² = 63%; P = 0.004), triglycerides (MD = −0.31, I² = 0%; P < 0.0001), and fasting plasma glucose (MD = −0.30, I² = 0%; P = 0.005). No significant differences existed in low density lipoprotein cholesterol (MD = -0.27, I² = 75%; P = 0.1), high density lipoprotein cholesterol (MD = -0.02, I² = 31%; P = 0.56), glycated hemoglobin (MD = -0.22, I² = 67%; P = 0.21), systolic blood pressure (MD = -1.62, I² = 0%; P = 0.17), or diastolic blood pressure (MD = -1.68, I² = 39%; P = 0.15).
Conclusion
This systematic review provides preliminary evidence supporting adjunctive berberine as a promising intervention for improving certain metabolic parameters in schizophrenia patients with metabolic syndrome. Larger, high-quality RCTs are needed to confirm these observations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Beijing Chaoyang Third Hospital, Beijing, China.
- Department of Psychiatry, Chongqing Eleventh People's Hospital, Chongqing, China.
- Department of Psychiatry, Chongqing Jiangbei Second Hospital, Chongqing, China.
- Department of Psychiatry, Yining People's Hospital, Yining, Xinjiang, China.
- Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China.
- Peking University Huilongguan Clinical Medical School, Beijing Huilongguan Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Xie, K., Tian, W., Zhang, Y., Zhang, Y., Li, J., Cao, D., & Pan, W. (2026). Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1846995
Vancouver
Xie K, Tian W, Zhang Y, Zhang Y, Li J, Cao D, et al. Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1846995
BibTeX
@article{Xie2026,
author = {Xie, Kankan and Tian, Wenzhong and Zhang, Yang and Zhang, Yan and Li, Jianmei and Cao, Dong and Pan, Weigang},
title = {Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysis},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1846995}
}
EUVIMED